| Biotech's Bargain Bin: Can Value Be Found With Bristol-Myers Squibb? Bud Labitan submitsBristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis.The Company’s products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. In September 2009, BMS acquired Medarex, Inc., and in December 2009, it divested the Mead Johnson Nutrition Company (MJN).Complete Story » seekingalpha.com |
The Prostate Cancer Quandary Scientists may soon be able to answer the agonizing question facing men with prostate cancer: Does their cancer need immediate treatment or can it be left alone? online.wsj.com |
Genoptix: Magic Formula Stock or Magic Value Trap? Gaurav Sharma submits:Looks like a good value stock.......now let's find out if its a trap.As of 07/30/2010 the stock has fallen 56% from its high.Cash = $140 M = 7.7$/shareMarket Cap = 300M = 17.19/shareFCF for 2009 = 30, 2008 = 22,2007 = 12.5Has had tremendous growth in the past.Does out of clinic blood evaluation and suggests treatments. Currently, oncologists are being squeezed. They are being paid the same amount even though costs are rising and hence they are looking to reduce expenses. Also, uninsured patients are increasing. Besides that competition is increasing as described below.Complete Story » seekingalpha.com |
Arena’s Lorqess: A Market Size Analysis Rockford Coscia submits: The week has finally arrived. This Thursday an FDA advisory panel will take on one of the most controversial drugs of recent memory. Arena’s (ARNA) Lorqess, also known as lorcaserin, will be evaluated ultimately on whether its benefits outweigh its side effects. I’ve written other articles about Lorqess’ valvulopathy “issue” and its odds of passing based on the Qnexa panel, but today I wanted to tackle the share price issue on approval by the FDA. My hopes are that this analysis will help readers to have a better understanding of where share prices should rest upon favorable panel review and ultimately if and when approval is gained. Let me start by saying that the potential sales estimation, and therefore underlying share price, is one of the most difficult estimations I’ve seen for biotechs. This seems largely due to the fact that, while obesity is a tremendously large potential market, it is grossly under treated. A statistician might say that the error bars associated with this sort of valuation are astronomically huge. Use the information presented here and elsewhere and come up with a figure you believe in and invest accordingly. Other attempts at this analysis have been presented here, here, and here.Complete Story » seekingalpha.com |
The Avon Foundation for Women Gala Celebrates Champions Who Change Women's Lives - Video NEW YORK, Oct. 27 /PRNewswire/ -- The 10th annual Avon Foundation for Women Gala tonight honored exceptional women and men for their efforts to end breast cancer and violence against women. The event, held at Cipriani 42nd Street in New York City, has raised more than $20 million for Avon philanthropy in the decade since it launched. The event was hosted by Reese Witherspoon, award-winning actress and Honorary Chair of the Avon Foundation for Women, and Andrea Jung, Chairman and CEO, Avon Products Inc., with a special musical performance by Melissa Etheridge. To view the multimedia as feedproxy.google.com |